Filing Details
- Accession Number:
- 0000950170-25-009848
- Form Type:
- 13D Filing
- Publication Date:
- 2025-01-27 19:00:00
- Filed By:
- Apeiron Investment Group Ltd.
- Company:
- Bionomics Limited
- Filing Date:
- 2025-01-28
- SEC Url:
- 13D Filing
Ownership Summary
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Apeiron Investment Group Ltd. | 0 | 72,618 | 0 | 72,618 | 72,618 | 4.5% |
| Apeiron Presight Capital Fund II, L.P. | 0 | 0 | 0 | 0 | 0 | 0% |
| Presight Capital Management I, L.L.C. | 0 | 0 | 0 | 0 | 0 | 0% |
| Fabian Hansen | 0 | 0 | 0 | 0 | 0 | 0% |
| Christian Angermayer | 0 | 72,618 | 0 | 72,618 | 72,618 | 4.5% |
Filing
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 2)
|
Neuphoria Therapeutics Inc. (Name of Issuer) |
Common Stock (Title of Class of Securities) |
64136E102 (CUSIP Number) |
Julien Hofer Beatrice, at 66 & 67 Amery Street, Sliema, O1, SLM1707 356 9960 9158 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
01/24/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 64136E102 |
| 1 |
Name of reporting person
Apeiron Investment Group Ltd. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
MALTA
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
72,618.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
4.5 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
CO |
SCHEDULE 13D
|
| CUSIP No. | 64136E102 |
| 1 |
Name of reporting person
Apeiron Presight Capital Fund II, L.P. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
0.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
PN |
SCHEDULE 13D
|
| CUSIP No. | 64136E102 |
| 1 |
Name of reporting person
Presight Capital Management I, L.L.C. | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
0.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13D
|
| CUSIP No. | 64136E102 |
| 1 |
Name of reporting person
Fabian Hansen | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
GERMANY
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
0.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
| CUSIP No. | 64136E102 |
| 1 |
Name of reporting person
Christian Angermayer | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
GERMANY
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
72,618.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
4.5 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock | |
| (b) | Name of Issuer:
Neuphoria Therapeutics Inc. | |
| (c) | Address of Issuer's Principal Executive Offices:
100 Summit Dr, Burlington,
MASSACHUSETTS
, 01803. | |
Item 1 Comment:
This Amendment No. 2 to Schedule 13D (this "Amendment No. 2") amends and supplements the statement on Schedule 13D filed with the United States Securities and Exchange Commission (the "SEC") on December 30, 2021, as amended to date (the "Schedule 13D"), relating to the ordinary shares, no par value per share (the "Ordinary Shares"), of Bionomics Limited, an Australian public company limited by shares. On December 23, 2024 (the "Effective Date"), the redomiciliation ("Redomiciliation") of Bionomics Limited was implemented under Australian law in accordance with a Scheme Implementation Agreement (as amended) between Bionomics and Neuphoria Therapeutics Inc., a Delaware corporation ("Neuphoria" or, the "Issuer"). The Redomiciliation was effected pursuant to a statutory Scheme of Arrangement under Australian law (the "Scheme"). As a result of the Redomiciliation, Bionomics became a wholly-owned subsidiary of Neuphoria, and each outstanding Ordinary Share and ADS were converted into shares of Common Stock, $0.00001 par value per share ("Common Stock") of the Issuer. Capitalized terms used herein without definition shall have the meaning set forth in the Schedule 13D | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | The information contained on the cover pages is incorporated by reference to this Item 5.
The information on the cover pages sets forth the aggregate number and percentage of shares of Common Stock outstanding beneficially owned by each of the Reporting Persons, based on 1,628,659 shares of Common Stock outstanding as of December 31, 2024. | |
| (b) | The information contained on the cover pages is incorporated by reference to this Item 5.
Apeiron is the record holder of the shares of Common Stock reported herein. Christian Angermayer is the majority shareholder of Apeiron and may be deemed to share beneficial ownership of the securities beneficially owned by Apeiron. | |
| (c) | On January 24, 2025, Apeiron sold 55,414 shares of Common Stock in an open market transaction on the Nasdaq Global Market at an average price per share of $10.8428. Except for the foregoing, during the past 60 days neither the Reporting Persons nor any Related Person has effected any transactions in the Ordinary Shares. | |
| (d) | None. | |
| (e) | This Amendment No. 2 is being filed to report that, as of the date hereof, the Reporting Persons do not beneficially own more than five percent of the outstanding Common Stock. | |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|
|
|
|
|
|
|